ABSTRACT
The encephalopathy caused by HIV, known clinically as HIV-associated dementia (HAD) and pathologically as HIV encephalitis (HIVE), results from intense infiltration of mononuclear cells, productive replication of the virus in monocyte-derived macrophages/microglia, abortive replication in astrocytes and activation of macrophages/microglia and astrocytes leading to neuronal degeneration in the brains of infected persons. Recent findings have suggested that development of HAD is based more on the activation process than on direct evidence of virus replication in the brain. Since HAD is based on the encephalitic process, major studies have been directed to the mechanisms regulating the inflammatory process. Monocyte chemoattractant protein 1, MCP-1, is a chemokine that is implicated in this process and also in the development of activation in the brain. In this review, we have attempted to identify mechanisms that induce expression of MCP-1 in the brain and the role that it plays in recruitment of mononuclear cells from blood to brain and in the activation processes of inflammatory and neural cells that lead to development of degenerative changes in the neuronal population.
INTRODUCTION
In recent years the incidence of HIV-associated dementia (HAD) as an AIDS-defining illness has actually increased (1-4) with more prevalence of minor cognitive/motor disorder than frank dementia (5, 6). Approximately 20% of AIDS patients develop neurological deficits severe enough to be diagnosed as dementia (1) and therefore, HAD still remains a significant independent risk factor for AIDS-related death.
The CNS has been thought to be an immunologically privileged organ. However, increasing evidence suggests that inflammation is actively involved in the pathogenesis of HAD (7-10). HIV encephalitis (HIVE), the pathologic correlate of HAD is characterized by the presence of unusually large numbers of HIV-infected macrophages in the brain, formation of multi-nucleated giant cells, activation of astrocytes and microglia, all accompanied by cytokine/chemokine dysregulation, and neuronal degeneration ( 7, [11] [12] [13] [14] . The highly productive infection in macrophages in the brain is also accompanied by an abortive infection in astrocytes (15) (16) (17) (18) . Although the primary cell types infected by HIV-1 in the brain are macrophages/microglia, and to a lesser extent, astrocytes but not neurons, the low numbers of infected cells in the brain do not correlate with the severity of encephalopathy. Rather, the severity of HAD/HIVE correlates with the presence of activated glial cells rather than with the presence and amount of HIV-infected cells in the brain and the current thinking about the disease is that CNS injury is mainly caused by the release of neurotoxic factors by immune-activated glial cells (7, 13).
The combined infection of macrophages/microglia and astrocytes leads to excessive production of viral gene products and host immune response factors, prominent among which is the monocyte chemoattractant protein-1 (MCP-1) (19, 20) . MCP-1, also known as CCL2, is produced in response to proinflammatory stimuli by a wide variety of cells, including macrophages, endothelial cells, microglia, and astrocytes (21) . MCP-1 attracts monocytes, macrophages, basophils, mast cells, T lymphocytes, natural killer (NK) cells, and dendritic cells to sites of injury, both peripherally and within the brain.
Numerous studies strongly suggest increased MCP-1 in CNS to be responsible for HIV-encephalitis (22) (23) (24) (25) (26) . It is overproduced during HIVE and accumulates in the CSF and brains of immunocompromised patients with HIV dementia (23) and HIVE (27, 28) and in macaques with SIV encephalitis (SIV-E) (26, 29, 30) . Serial analysis of cerebrospinal fluid (CSF) in HIV-infected individuals (22) and in SIV-infected macaques (26) showed that MCP-1 levels increase in CSF before the onset of clinical neurological disease and thus can be used as a prognostic factor for later development of HIV-encephalitis.
In the following sections the role of MCP-1 will be examined in different aspects of the processes that lead to development of HAD.
REGULATION OF MCP-1 IN ASTROCYTES
Astrocytes are the predominant cell type in CNS, accounting for almost 70% cells in the brain. Although astrocytes do not support efficient replication of HIV-1, they are thought to be a substantial contributor to HIVrelated neuropathogenesis. MCP-1 expression in astrocytes, the main producer of this chemokine in the CNS, is increased following infection of the cells with HIV-1 (23, 31, 32) . One of the factors that have been shown to activate MCP-1 production from astrocytes is the HIV-1 transactivator viral protein, Tat. Tat has been shown to upregulate the expression of MCP-1 in human fetal astrocytes (23, 33, 34) . The mechanism of this phenomenon was explored in subsequent studies (33) using a CCL2 promoter containing reporter constructs. Tat induced MCP-1 expression in this study was found to be regulated at the transcriptional level through activation of AP-1 and NF-κB transcription factors. Furthermore, in the later studies by Sheng et al, the use of a synthetic ligand against κ-opioid receptor (U50, 488) resulted in inhibition of Tat-induced MCP-1 production in primary human astrocytes (35) . This suppression was mediated by down regulation of Tat-induced NF-κB activation (35) . In Tat-treated human astrocytes, inhibition of protein kinase C (PKC) led to a decrease in MCP-1 production (36, 37) . This data suggested that Tat may be able to influence MCP-1 expression by acting as a cytokine itself (37) . Other evidence suggested that induction of MCP-1 in Tat-treated cells may be further increased by Tat's ability to induce the expression of other cytokines that have direct effects on MCP-1 production (38-40).
We examined SHIV 89.6P, an HIV/SIV chimeric that expresses HIV envelope, for its ability to induce changes in MCP-1 release in the astrocytic cell line CCF-STTG1 and found that, similar to findings reported for Tat (23, 33, 34) , the infectious virus, SHIV89.6P, also caused increase in MCP-1 release from astrocytes as compared to untreated control cells (data not shown). Several intracellular pathways were activated following SHIV treatment of astrocytes; however, not all of these pathways were found to have a direct effect on MCP-1 expression. Exposure of astrocytes to SHIV89.6P or Tat resulted in activation of AKT, JNK and ERK1/2 MAP kinases (data not shown). Inhibition of these kinases with the use of pharmacological inhibitors resulted in decreased expression of MCP-1; however none of the inhibitors were able to completely abrogate the expression of MCP-1 ( Figure 1A ). This indicated that these pathways most likely operate together to converge on a common transcription factor such as NF-κB, which subsequently mediates MCP-1 expression. Previous studies have alluded to the role of NF-κB in modulation of MCP-1 expression (33, 35) . Our studies supported this hypothesis showing that NF-κB in astrocytes treated with SHIV89.6P translocated to the nucleus of the infected cells ( Figure 1B ). These findings were further confirmed by pre-treating the cells with the specific inhibitor of NF-κB prior to virus exposure.
Significant inhibition of MCP-1 was observed in the presence of the pharmacological inhibitor for NF-κB, thus underscoring the role of this transcription factor in virus induced MCP-1 expression. Figure 2 is a schematic illustrating the possible signaling pathway (s) that are activated by SHIV or viral protein Tat to mediate the up regulation of MCP-1 expression in astrocytes. Upon binding of SHIV/Tat there is an activation of MAP Kinase signaling which in turn can initiate the phosphorylation of JNK, ERK1/2, or the AKT pathways. All of these pathways culminate in translocation of the transcription factor NF-κB into the nucleus, its binding to the MCP-1 promoter followed by increased transcription.
REGULATION OF MCP-1 IN MACROPHAGES
Study by Mengozzi et al on HIV-infection of human monocyte-derived macrophages demonstrated increased expression and secretion of MCP-1 by macrophages productively infected with either R5 or X4-coreceptor utilizing viruses (28) . Our previous studies on infection in rhesus macrophages with SHIV KU2 , an X4 virus or SIVmac 251, an R5 virus, also showed that the infection in these cells led to increased production of MCP-1 (29) . This was demonstrated in cell culture experiments and in brain sections where there was co-localization of markers specific for macrophages and enhanced expression of MCP-1 (30).
Exposure of macrophages or microglia to Tat protein also resulted in superinduction of MCP-1 in a concentration dependent manner (41, 42) . In a study of the effects of Tat on cultured microglial cells, Eugenin et al showed that Tat caused enhanced secretion of MCP-1 and this was associated with actin rearrangement, formation of microglial processes (42) and migration of microglia to areas of viral infiltration within the brain. Not only did the infection lead to enhanced production of MCP-1 but exogenous application of MCP-1 to infected CD4 + peripheral blood mononuclear cells resulted in enhanced virus replication (43).
MCP-1 AND THE BLOOD BRAIN BARRIER
Macrophages are terminally differentiated cells that originate from monocytes and cannot undergo further cell division. Therefore, the large numbers of macrophages in the HIV-infected brain can only be explained by pathophysiological changes in which large numbers of monocytes are recruited into the brain from the blood, across the tight junctioned endothelial cells comprising the blood-brain barrier (BBB). MCP-1 is known to contribute in neuropathogenesis by facilitating the recruitment of infected and/or activated monocytes into the brain (20, 22, 26, 44) . Enhanced transmigration of HIV-infected leukocytes across an astrocyte/endothelial cell coculture model of BBB in response to MCP-1 has been observed compared to transmigration of uninfected leukocytes (20) . This increase in migration of HIV-infected leukocytes coincided with the increased expression of the MCP-1 receptor (CCR2) on HIV-infected leukocytes. MCP-1 mediated transmigration of leukocytes across BBB has also been demonstrated to be dependent upon expression of ICAM-1 and E-selectin adhesion molecules on endothelial cells (45) . The enhanced expression of ICAM-1, VCAM-1 and Eselectin correlate with the extent of leukocyte infiltration in HIV-encephalitis and various other CNS inflammatory diseases (46) (47) (48) .
The production of MCP-1 by macrophages (28) , astrocytes (45) and brain endothelial cells (49) provided compelling evidence that this chemokine is responsible for the transmigration of lymphocytes and monocytes across the BBB into the CNS during inflammatory diseases. In addition to increased expression of MCP-1 by HIV/SIV infected macrophages, the interaction of HIV-infected macrophages with brain microvascular endothelial cells results in further up regulation of MCP-1 expression in macrophages (50) . In a further study, Weiss et al , showed that treatment of cocultures on the astrocyte side with HIVTat results in enhanced secretion of MCP-1 from astrocytes but not from endothelial cells (51) .
Recent studies indicated that MCP-1 not only functions as a contributor to enhanced infection in the brain by recruiting large number of macrophages (virus host cells) in the brain (23) but also plays a major factor in BBB disruption (52) . Both in vitro and in vivo studies suggest that MCP-1 can directly alter the permeability of BBB by altering expression or redistribution of occludin, claudin-5, zona occludens (ZO)-1 and ZO-2 tight junction proteins (TJPs) (52, 53) . Further, the MCP-1 mediated changes in the BBB were absent in the mice lacking the CCR2 receptor and were reduced when mice were depleted of monocyte/macrophages by clondronate liposomes (52) suggesting that recruitment of monocytes by MCP-1 might contribute to BBB disruption. This was further confirmed by a detailed in vitro study by Eugenin et al using coculture model of brain endothelial cells and astrocytes in which they demonstrated enhanced BBB permeability, reduced expression TJPs and upregulated expression of matrix metalloproteinase (MMP)-2 and MMP-9 on transmigration of HIV-infected monocytes in response to MCP-1 (20) .
PERSPECTIVE
The encephalopathy caused by HIV is unique among neurovirulent viral infection because HIV does not cause infection in neurons. However, the multiplicity of a large number of toxic factors induced by the virus in infected macrophages and astrocytes in the brain contribute to degenerative effects in neurons. MCP-1 clearly has an important role among these various factors by contributing to neuropathogenesis by both facilitating migration of infected and/or activated monocytes into the brain where they become host cells for HIV-1 replication and by activating macrophages, microglia and astrocytes that results in release of a number of potent neurotoxins.
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